Rapamycin and Alzheimer's disease: Time for a clinical trial?

Matt Kaeberlein; Veronica Galvan

doi:10.1126/scitranslmed.aar4289

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Matt Kaeberlein, Veronica Galvan

Cellular & Integrative Physiology

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Original language	English (US)
Article number	eaar4289
Journal	Science translational medicine
Volume	11
Issue number	476
DOIs	https://doi.org/10.1126/scitranslmed.aar4289
State	Published - Jan 23 2019

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1126/scitranslmed.aar4289

Cite this

@article{d66cd3656b3f43ada490f0b13f0c7b39,

title = "Rapamycin and Alzheimer's disease: Time for a clinical trial?",

abstract = "The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.",

author = "Matt Kaeberlein and Veronica Galvan",

note = "Funding Information: M.K. and V.G. are supported by the University of Washington and UT Health San Antonio Nathan Shock Centers of Excellence in the Basic Biology of Aging, as well as NIH grants P30AG013280 and P30AG013319.",

year = "2019",

month = jan,

day = "23",

doi = "10.1126/scitranslmed.aar4289",

language = "English (US)",

volume = "11",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "476",

}

TY - JOUR

T1 - Rapamycin and Alzheimer's disease

T2 - Time for a clinical trial?

AU - Kaeberlein, Matt

AU - Galvan, Veronica

N1 - Funding Information: M.K. and V.G. are supported by the University of Washington and UT Health San Antonio Nathan Shock Centers of Excellence in the Basic Biology of Aging, as well as NIH grants P30AG013280 and P30AG013319.

PY - 2019/1/23

Y1 - 2019/1/23

N2 - The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

AB - The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=85060368800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060368800&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aar4289

DO - 10.1126/scitranslmed.aar4289

M3 - Review article

C2 - 30674654

AN - SCOPUS:85060368800

VL - 11

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 476

M1 - eaar4289

ER -

Rapamycin and Alzheimer's disease: Time for a clinical trial?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this